Document Classification

Section Type: METHODS

Text: Patients randomly assigned to sequential treatment received fluorouracil 500 mg/m (2), epirubicin 75 mg/m (2), and cyclophosphamide 500 mg/m (2) (FEC-75) on day 1 of a 21-day cycle for four cycles followed by paclitaxel 80 mg/m (2) and trastuzumab 2 mg/kg (after a 4 mg/kg loading dose) once per week for 12 weeks, while those randomly assigned to the concurrent treatment group received paclitaxel and trastuzumab once per week for 12 weeks followed by four cycles of FEC-75 (on day 1 of each 21-day cycle) and once-weekly trastuzumab, in the same doses as the sequential group.